Novartis AG (NVS)

98,35 +1,07 (+1,10%) Börsenschluss: 04:00PM EDT

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 76.057

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Vasant Narasimhan M.D.	Chief Executive Officer	8,04M	N/A	1976
Mr. Harry Kirsch	Chief Financial Officer	4M	N/A	1965
Mr. Victor Bulto	President of US	3,29M	N/A	1978
Dr. Patrick Horber M.D.	President of International	7,33M	N/A	1970
Dr. Steffen Lang Ph.D.	President of Operations	2,34M	N/A	1967
Paul Penepent	Head of Group Financial Reporting and Accounting	N/A	N/A	N/A
Dr. Samir Shah M.D.	Global Head of Investor Relations	N/A	N/A	1962
Dr. Klaus Moosmayer Ph.D.	Chief Ethics, Risk & Compliance Officer	1,56M	N/A	1968
Ms. Karen L. Hale	Chief Legal Officer	2,35M	N/A	1968
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer	2,11M	N/A	1968

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Corporate Governance

Novartis AGs ISS Governance QualityScore, Stand 1. April 2024, lautet 1. Die grundlegenden Scores sind Audit: 1, Vorstand: 2, Shareholderrechte: 1, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.